异烟肼预防肯尼亚HIV暴露未感染婴儿结核分枝杆菌感染的随机对照试验
该随机非盲对照试验纳入300名6周龄无已知结核暴露的HIV暴露未感染婴儿,1:1随机接受12个月每日异烟肼(10 mg/kg)或不接受异烟肼。严重不良事件两组相似。结论认为需进一步研究结核预防治疗以预防或延迟HIV暴露未感染高危婴儿的原发感染。
要点
- 异烟肼组12个月结核感染率7.6%,非异烟肼组13.5%,风险比0.53但无统计学意义。
- 感染差异主要由结核菌素皮肤试验阳性驱动,异烟肼组8.6% vs 非异烟肼组18.1%。
- 严重不良事件两组相似(14.0% vs 10.7%),无异烟肼相关不良事件。
核心结论
- 在肯尼亚HIV暴露未感染婴儿中,12个月每日异烟肼预防未显著降低12个月时结核分枝杆菌感染患病率。
- 需进一步研究结核预防治疗以预防或延迟HIV暴露未感染及其他高危婴儿的原发结核感染。
研究设计与样本
- 随机非盲对照试验,在肯尼亚纳入6周龄无已知结核暴露的HIV暴露未感染婴儿。
- 300名婴儿1:1随机接受12个月每日异烟肼(10 mg/kg)或不接受异烟肼,2名因HIV感染排除,298名纳入分析。
- 主要终点为12个月末结核分枝杆菌感染,通过干扰素-γ释放试验(QuantiFERON-TB Gold Plus)和/或结核菌素皮肤试验评估。
主要发现
- 12个月随访时结核感染总患病率为10.6%(28/265)。
关键数值与推荐
- 异烟肼剂量为每日10 mg/kg,持续12个月。
- 主要终点评估采用QuantiFERON-TB Gold Plus和/或结核菌素皮肤试验(TST在首例参与者退出后6个月加入)。
- 12个月保留率96.3%(287/298),88.9%(265/298)有主要结局数据。
临床怎么用
- 对于HIV暴露未感染婴儿,异烟肼预防治疗未显示显著降低结核感染风险,但耐受性良好。
- 临床决策需权衡个体风险,当前证据尚不足以常规推荐异烟肼用于该人群原发感染的预防。
局限性
- 研究为非盲设计。
- 结核菌素皮肤试验在首例参与者退出后6个月加入,可能影响感染评估的一致性。
- 样本量可能不足以检测主要终点的统计学显著性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunodeficiency virus (HIV)-exposed uninfected (HEU) infants in endemic settings are at high risk of tuberculosis (TB). For infants, progression from primary Mycobacterium tuberculosis (Mtb) infection to TB disease can be rapid. We assessed whether isoniazid (INH) prevents primary Mtb infection. METHODS: We conducted a randomized nonblinded controlled trial enrolling HEU infants 6 weeks of age without known TB exposure in Kenya. Participants were randomized (1:1) to 12 months of daily INH (10 mg/kg) vs no INH. Primary endpoint was Mtb infection at end of 12 months, assessed by interferon-γ release assay (QuantiFERON-TB Gold Plus) and/or tuberculin skin test (TST, added 6 months after first participant exit). RESULTS: Between 15 August 2016 and 6 June 2018, 416 infants were screened, with 300 (72%) randomized to INH or no INH (150 per arm); 2 were excluded due to HIV infection. Among 298 randomized HEU infants, 12-month retention was 96.3% (287/298), and 88.9% (265/298) had primary outcome data. Mtb infection prevalence at 12-month follow-up was 10.6% (28/265); 7.6% (10/132) in the INH arm and 13.5% (18/133) in the no INH arm (7.0 vs 13.4 per 100 person-years; hazard ratio, 0.53 [95% confidence interval {CI}, .24-1.14]; P = .11]), and driven primarily by TST positivity (8.6% [8/93] in INH and 18.1% [17/94] in no INH; relative risk, 0.48 [95% CI, .22-1.05]; P = .07). Frequency of severe adverse events was similar between arms (INH, 14.0% [21/150] vs no INH, 10.7% [16/150]; P = .38), with no INH-related adverse events. CONCLUSIONS: Further studies evaluating TB preventive therapy to prevent or delay primary Mtb infection in HEU and other high-risk infants are warranted. CLINICAL TRIALS REGISTRATION: NCT02613169.
引用
- LaCourse SM, Richardson BA, Kinuthia J, et al. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants. Clin Infect Dis. 2021. PMID: 32564076. doi:10.1093/cid/ciaa827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。